𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: A study of five different suppositories

✍ Scribed by Dr. T. van Laar; E. N. H. Jansen; C. Neef; M. Danhof; R. A. C. Roos


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
568 KB
Volume
10
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

The pharmacokinetics and clinical effects of apomorphine after rectal administration were determined in five patients with idiopathic Parkinson's disease (PD). Three different pharmaceutical formulations were tested: a rectal solution of apomorphine (10 or 15 mg), a gelatin suppository (25 and 50 mg), and a Witepsol‐H15 suppository (50 and 100 mg). The pharmacokinetics of apomorphine were determined by measuring plasma concentrations using a sensitive and specific high‐performance liquid chromatography method. The mean bioavailability varied between 14.7% and 40.2%, which was the bioavailability until the end of clinical benefit. Also, despite the differences in dose, the values of the Cmax were similar, with average values of 12.7‐25.6 ng/ml. Wide differences in Tmax were observed, with values varying between 16 min for the enema and 127.5 min for the Witepsol‐H15 100‐mg suppository. The time course of the clinical effect was determined by assessing the time needed for walking a 25‐m course and by calculating a tremor and dyskinesia score. Onset of effect was similar for each of the preparations, with an average onset time of 14‐28 min. Significant differences with respect to the duration of the effect were observed. The duration of effect after administration of the Witepsol‐H15 100‐mg suppository was 156 ± 43 min versus 50 ± 13 min after rectal administration of the apomorphine solution. These results show that rectal administration of apomorphine may present an alternative to subcutaneous administration. The sustained‐release properties of the Witepsol‐H15 suppositories are especially of interest in the treatment of on‐off fluctuations in PD.


📜 SIMILAR VOLUMES


Efficacy of long-term continuous subcuta
✍ Pedro J. García Ruiz; Ángel Sesar Ignacio; Begoña Ares Pensado; Alfonso Castro G 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB 👁 2 views

## Abstract Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long‐term treated with CSAI. We reviewed data from 82 patie

A new sublingual formulation of apomorph
✍ Dr. T. van Laar; C. Neef; M. Danhof; K. I. Roon; R. A. C. Roos 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 503 KB

## Abstract A new formulation of a sublingual tablet with 10 mg apomorphine was examined in 13 patients with Parkinson's disease. Vitamin C (250 mg) was added sublingually to lower the salivary pH. Four patients received sublingual apomorphine and nine received sublingual apomorphine as well as vit

Clinical efficacy of istradefylline (KW-
✍ Yoshikuni Mizuno; Kazuko Hasegawa; Tomoyoshi Kondo; Sadako Kuno; Mitsutoshi Yama 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 164 KB 👁 1 views

## Abstract The objectives of this study were to evaluate the efficacy of istradefylline at an oral dose of 20 mg or 40 mg once daily for 12 weeks in Parkinson's disease (PD) patients with motor complications on levodopa therapy based on the change in the daily OFF time compared with placebo and to

A clinical and pharmacokinetic case stud
✍ G. K. Wenning; M. T. O'Connell; P. N. Patsalos; Dr. N. P. Quinn 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract We studied the relationship between levodopa response and antituberculous treatment in a patient with idiopathic Parkinson's disease whose parkinsonism deteriorated when treatment with rifampicin and isoniazid (Rifinah) for pulmonary tuberculosis was started. A levodopa challenge test w

Safety of entacapone and apomorphine coa
✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic

Camptocormia in Japanese patients with P
✍ Morinobu Seki; Kazushi Takahashi; Atsuo Koto; Ban Mihara; Yoko Morita; Kazuo Iso 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 264 KB 👁 1 views

## Abstract ## Objective: The aim of this work was to investigate the prevalence of camptocormia and the clinical characteristics of patients with camptocormia in a large population of PD patients. ## Background: Although camptocormia has been recognized as a prominent phenomenon in PD, the prev